Niemann-Pick disease type C therapy Miplyffa became commercially available in late November and by the year’s end, a total of 109 prescription enrollment forms had been submitted. The company estimates there are around 900 patients with the disease in the
read moreHaving spent the better part of the decade grappling with bankruptcy bids and opioid settlements, troubled drugmakers Mallinckrodt and Endo have decided to join forces to create a more flexible company and ultimately spin off their sizeable generics businesses. More:
read more
EC extends brexpiprazole indication to include adolescents More: Rxulti approved in the European Union for adolescent schizophrenia Source: News
read more
Immunoglobulin therapy improves mobility in phase 2/3 study More: Grifols clinical trial shows positive results for post-polio patients Source: News
read moreTreatments for autoimmune diseases and those in orphan markets are on the up and up, as are drugmakers’ first launches, according to the latest edition of Trinity Life Sciences’ annual Drug Index. The report looked at several factors to rank
read moreOn track to meet their long-stated capacity goal for multiple myeloma therapy Carvykti in 2025, Johnson & Johnson and Legend Biotech are already planning the next phase of their cell therapy manufacturing expansion. More: J&J, Legend to invest 0M in
read more© 1994 - 2026 B.M. Pharmaceuticals